HomeCompareMZTFF vs ABBV

MZTFF vs ABBV: Dividend Comparison 2026

MZTFF yields 3.87% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MZTFF wins by $1524.30M in total portfolio value· pulled ahead in Year 2
10 years
MZTFF
MZTFF
● Live price
3.87%
Share price
$75.05
Annual div
$2.91
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1524.41M
Annual income
$1,452,376,059.50
Full MZTFF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — MZTFF vs ABBV

📍 MZTFF pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMZTFFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MZTFF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MZTFF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MZTFF
Annual income on $10K today (after 15% tax)
$329.24/yr
After 10yr DRIP, annual income (after tax)
$1,234,519,650.58/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, MZTFF beats the other by $1,234,498,594.57/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MZTFF + ABBV for your $10,000?

MZTFF: 50%ABBV: 50%
100% ABBV50/50100% MZTFF
Portfolio after 10yr
$762.25M
Annual income
$726,200,415.63/yr
Blended yield
95.27%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

MZTFF
No analyst data
Altman Z
0.4
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MZTFF buys
0
ABBV buys
0
No recent congressional trades found for MZTFF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMZTFFABBV
Forward yield3.87%3.06%
Annual dividend / share$2.91$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$1524.41M$102.3K
Annual income after 10y$1,452,376,059.50$24,771.77
Total dividends collected$1519.24M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MZTFF vs ABBV ($10,000, DRIP)

YearMZTFF PortfolioMZTFF Income/yrABBV PortfolioABBV Income/yrGap
1$11,475$774.69$11,550$430.00$75.00ABBV
2← crossover$13,939$1,661.55$13,472$627.96+$467.00MZTFF
3$18,688$3,772.82$15,906$926.08+$2.8KMZTFF
4$29,451$9,454.31$19,071$1,382.55+$10.4KMZTFF
5$59,361$27,848.73$23,302$2,095.81+$36.1KMZTFF
6$168,436$104,919.96$29,150$3,237.93+$139.3KMZTFF
7$736,694$556,467.21$37,536$5,121.41+$699.2KMZTFF
8$5,337,492$4,549,229.28$50,079$8,338.38+$5.29MMZTFF
9$67,318,712$61,607,596.45$69,753$14,065.80+$67.25MMZTFF
10$1,524,407,082$1,452,376,059.50$102,337$24,771.77+$1524.30MMZTFF

MZTFF vs ABBV: Complete Analysis 2026

MZTFFStock

Mizrahi Tefahot Bank Ltd., together with its subsidiaries, provides a range of international, commercial, domestic, and personal banking services to individuals and businesses in Israel, Switzerland, and internationally. It operates through six segments: Household, Small Business, Private Banking, Commercial Banking, Business Banking, and Financial Management. The company offers checking, savings, and deposits accounts; and loans, such as instant, home renovation, auto, all-purpose, student, and business; mortgages; and credit cards. It also provides foreign trade services, including import, export, and documentary credit; bank guarantees; transactions in foreign currency, which include trading in derivative instruments, factoring services, and investments in deposits and securities; financing of real estate and construction projects; mergers and acquisitions services; and private and online banking services. In addition, the company offers capital market services, including consultancy for capital market activities, distribution of mutual funds, management of securities portfolios for clients, pension advisory service, trust services, provision of registration services; operates provident funds, mutual funds, and insurance incidental to mortgages; and participates in syndication transactions, as well as engages in credit operations. As of December 31, 2021, it operated through a network of 225 branches and business centers, including 52 Bank Yahav branches and 29 Union Bank branches in Israel; and two bank affiliates. The company was formerly known as United Mizrahi Bank Limited and changed its name to Mizrahi Tefahot Bank Ltd. in November 2005. The company was incorporated in 1923 and is headquartered in Ramat Gan, Israel.

Full MZTFF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this MZTFF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MZTFF vs SCHDMZTFF vs JEPIMZTFF vs OMZTFF vs KOMZTFF vs MAINMZTFF vs JNJMZTFF vs MRKMZTFF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.